Stockreport

ALX Oncology outlines pivotal trial readiness by end of 2026 with expanded ASPEN-09 study and $150M financing [Seeking Alpha]

ALX Oncology Holdings Inc.  (ALXO) 
PDF Barbara Klencke as the permanent Chief Medical Officer, following her interim leadership since September 2025. Lettmann stated, “We're beyond fortunate to add Barb durin [Read more]